Vergoeding 2020-2024 voor ATC-subgroep C10AX : Overige antilipaemica
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| C10AX06 Omega-3-vetzuurpreparaat (Vazkepa ®) | . | . | . | 23.446 | 395.820 |
| C10AX09 Ezetimib (Ezetrol ®) | 6.281.900 | 4.933.200 | 5.317.600 | 5.532.200 | 11.810.700 |
| C10AX12 Lomitapide (Lojuxta ®) | 1.563.700 | 2.142.400 | 1.922.200 | 1.599.500 | 1.187.200 |
| C10AX13 Evolocumab (Repatha ®) | 48.273.000 | 55.537.900 | 66.601.700 | 76.865.900 | 79.704.900 |
| C10AX14 Alirocumab (Praluent ®) | 41.041.300 | 47.665.500 | 58.487.900 | 65.795.800 | 72.356.800 |
| C10AX15 Bempedoinezuur (Nilemdo ®) | . | . | . | 185.320 | 850.210 |
| C10AX16 Inclisiran (Leqvio ®) | . | . | 2.819.700 | 6.144.900 | 9.787.000 |
| C10AX18 Volanesorsen (Waylivra ®) | . | . | . | . | 134.380 |
| Totaal | 97.159.900 | 110.279.000 | 135.149.100 | 156.147.066 | 176.227.010 |